Mucormycosis and glucose-regulated protein 78 in COVID-19: Amenable to statin treatment?

Vuorio, Alpo; Kovanen, Petri T

Vuorio, Alpo; Kovanen, Petri T.

Vuorio A; Department of Forensic Medicine, University of Helsinki, Helsinki, Finland.
Kovanen PT; Mehiläinen Airport Health Centre, Vantaa, Finland.

J Intern Med ; 290(4): 931-933, 2021 10.

Article in English | MEDLINE | ID: covidwho-1270860

Subject(s)

COVID-19/therapy; Heat-Shock Proteins/physiology; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Mucormycosis/epidemiology; SARS-CoV-2/physiology; COVID-19/epidemiology; Diabetes Complications/complications; Endoplasmic Reticulum Chaperone BiP; Humans; Hyperlipoproteinemia Type II/complications; Hyperlipoproteinemia Type II/drug therapy; Mucormycosis/therapy; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / SARS-CoV-2 / COVID-19 / Heat-Shock Proteins / Mucormycosis Type of study: Observational study Topics: Long Covid Limits: Humans Language: English Journal: J Intern Med Journal subject: Internal Medicine Year: 2021 Document Type: Article Affiliation country: Joim.13347

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google